See You Tonight at “Biotech’s Back in Seattle”

I’m getting ready for one of Xconomy’s biggest events of the year—“Biotech’s Back in Seattle“—which will be held tonight at PATH’s new headquarters in South Lake Union. More than 200 people have snapped up tickets so far, and only six seats are left at the time I’m writing this. So if you missed the last announcement before Thanksgiving, this is your last chance to register.

Tonight’s event will bring together some of the leaders in the Seattle biotech community for a conversation about what can be done to sustain some of the region’s newfound momentum. Dendreon’s Mitch Gold, Seattle Genetics’ Clay Siegall, Calistoga Pharmaceuticals’ Carol Gallagher, and Alder Biopharmaceuticals Randy Schatzman will be part of a feature panel in which they will take questions both from me and from you in the audience.

This is the second year in a row that Xconomy has scheduled an event right after the Thanksgiving break, and it reminds me of how thankful I am for all the support this community has given my colleagues and me as we pursue our dream in online journalism and community building. So special thanks tonight go out to PATH as the event host; as well as our event sponsors: Christensen O’Connor Johnson & Kindness, Cooley, Fenwick & West, and Wells Fargo Insurance Services.

Xconomy Seattle also has a fast-growing roster of 14 underwriters at last count who provide long-term support for our journalism and events like this one tonight. The group includes Alexandria Real Estate Equities, AMRI, Christensen O’Connor Johnson & Kindness, Cooley, Davis Wright Tremaine, Fenwick & West, the Institute for Systems Biology, Invest Northern Ireland, J. Robert Scott Executive Search, the Kauffman Foundation, the Science and Technology Directorate of the U.S. Department of Homeland Security, Seed IP, Swedish Medical Center, and Wells Fargo Insurance Services. We also have long-term support from three venture members—Arch Venture Partners, Vulcan Capital, and WRF Capital.

Of course, I can’t forget to thank our loyal and growing audience of readers for all your support and encouragement. See you there tonight.

Author: Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.